Crysvita sales push Ultragenyx ahead for the quarter

Sales of Ultragenyx's Crysvita hint at the XLH therapy's launch trajectory as it drove the biotech's revenues for the quarter.

Ultragenyx and

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE